QBIO
has a float of just 18.6 million shares. The stock is trading on a stick of dynamite. We have seen this explosive character several times in the past few months. This stock can take off like a rocket. On three separate occasions, we have seen QBIO shares leap by 50-100% in less than a week in the past 6 months.
Right now, we are seeing a “bullish flag pattern” following the burst to the upside that hit toward the end of March. That sprint has been consolidated in a healthy manner at this point, and a follow-through move to the upside could be primed.
About QBIO
QBIO (Q BioMed Inc.) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus.
Q BioMed Inc. is a biotech acceleration and commercial-stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Key Points:
• QBIO is moving into commercial-stage for its FDA-approved cancer drug, Strontium89.. ie, here comes the payoff
• QBIO has a small trading float of just 18.6M, which suggests the stock could launch higher on any additional influx of interest.
• QBIO is also developing a key potential treatment for COVID-19 and other infectious diseases, including influenza
• QBIO is coming off an RSI trough under 30 in mid-March, pointing to a massively oversold stock now heading back the other way, and consolidating in a nice “Bullish Flag” breakout pattern
• QBIO is planning on uplisting to the Nasdaq, which is often a major bull catalyst for OTC stocks